Fulcrum Therapeutics CEO Alex Sapir receives $7M in 2023
Fulcrum Therapeutics reports 2023 executive compensation
By ExecPay News
Published: April 19, 2024
Fulcrum Therapeutics reported fiscal year 2023 executive compensation information on April 19, 2024.
In 2023, six executives at Fulcrum Therapeutics received on average a compensation package of $2.6M, a 44% increase compared to previous year.
Average pay of disclosed executives at Fulcrum Therapeutics
Alex C. Sapir, Chief Executive Officer, received $7M in total. 92% of Sapir's compensation, or $6.4M, was in option awards. Sapir also received $150K in non-equity incentive plan, $369K in salary, as well as $72K in other compensation.
Curtis Oltmans, Chief Legal Officer, received a compensation package of $2.3M, which increased by 69% compared to previous year. 75% of the compensation package, or $1.7M, was in option awards.
Mel Hayes, Executive Vice President, Patient Affairs, earned $2.2M in 2023.
Alan Musso, Chief Financial Officer, received $1.9M in 2023.
Bryan Stuart, Chief Executive Officer, earned $1.9M in 2023, a 53% decrease compared to previous year.
Robert J. Gould, Chief Executive Officer, received $425K in 2023, which increases by 259% compared to 2022.
Related executives
Alex Sapir
Fulcrum Therapeutics
Chief Executive Officer
Bryan Stuart
Fulcrum Therapeutics
Chief Executive Officer
Robert Gould
Fulcrum Therapeutics
Chief Executive Officer
Alan Musso
Fulcrum Therapeutics
Chief Financial Officer
Curtis Oltmans
Fulcrum Therapeutics
Chief Legal Officer
Mel Hayes
Fulcrum Therapeutics
Executive Vice President, Patient Affairs
You may also like
Source: SEC filing on April 19, 2024.